Oregon Hasn’t Blocked Any Healthcare Deals Despite Oversight Law Dana Gibbon was 18 weeks pregnant with her first baby when her OB-GYN told her at an appointment that she wouldn’t be her doctor anymore. The clinic in Corvallis, Oregon, where she had been receiving care, had closed its OB-GYN services. The doctor said all of the clinic’s OB-GYNs had resigned, leaving patients like Gibbon scrambling to find new providers. The closure came two years after UnitedHealth Group’s subsidiary, Optum Oregon, acquired the clinic. The company cited a national shortage of physicians as a reason for the staff exodus, arguing that it was difficult to replace departing doctors and that remaining staff faced increased workloads. The Corvallis clinic’s closure highlights a broader issue in Oregon’s healthcare landscape, where a 2021 law aimed to prevent harmful mergers and acquisitions has yet to block any major deals. The law, which gave the state health department broad authority to review and potentially block hospital, hospice, and medical practice mergers, was designed to counteract industry consolidation that critics say drives up costs and reduces competition. Lawmakers argued the law would protect patients by ensuring transactions made sense and did not harm access to care. Despite the law’s intent, Oregon has not formally blocked a single transaction or issued fines. While the oversight program is credited with prompting the withdrawal of two high-profile deals—a Portland-area hospital merger and the acquisition of a Medicaid provider—supporters say its effectiveness has fallen short. Dr. John Santa, a retired physician and former member of the Oregon Health Policy Board, called the program “so disappointing” and noted that its outcomes “fell so short of what I expected.#unitedhealth_group #dana_gibbon #optum_oregon #clayton_dubilier_rice #oregon_health_department
UnitedHealth Group's Share Price Plummets 46%: Is It Undervalued? UnitedHealth Group (UNH) has experienced a significant decline in its stock price, with a 46.3% drop over the past year. The stock recently closed at $269.54, reflecting a 5.6% decline in the last week, 7.1% over 30 days, and a 19.9% year-to-date drop. Investors are now questioning whether the company’s valuation has been overly adjusted or if the market has priced in too much pessimism. Analysts and valuation tools suggest the stock may be undervalued. A Discounted Cash Flow (DCF) analysis estimates the company’s intrinsic value at $816.71 per share, implying the current price is approximately 67% below this figure. This projection is based on UnitedHealth Group’s projected free cash flow of $27.8 billion in 2030, with estimates extending through 2035. The DCF model highlights a potential gap between the stock’s current price and its long-term cash flow potential. The company’s price-to-earnings (P/E) ratio of 20.29x also places it below industry and peer averages. The Healthcare sector’s average P/E is 21.22x, while the peer group average is 18.82x. A proprietary “Fair Ratio” calculation by Simply Wall St suggests a P/E of 37.06x, further indicating the stock may be undervalued relative to its growth prospects and risk profile. Investors are divided on the company’s future outlook, with differing narratives shaping valuation expectations. Some argue the stock could approach a Fair Value of $625 per share, while others suggest a lower range near $284. This divergence underscores how market perceptions and assumptions about revenue, earnings, and margins can lead to conflicting conclusions.#healthcare_sector #unitedhealth_group #discounted_cash_flow #simply_wall_st #free_cash_flow
